DUBLIN, January 28, 2022 /PRNewswire/ — The “Market Spotlight: Hyperactive Bladder” report has been added to from ResearchAndMarkets.com offer.
Overactive bladder is characterized by urinary urgency and is usually accompanied by increased frequency of urination, nocturia, and incontinence. The disease affects men and women around the world and has a negative effect on the quality of life.
The prevalence and severity of symptoms increase with age, and overactive bladder symptoms persist for years in the majority of patients. Postmenopausal status has been associated with an increased risk of overactive bladder in women, while in men, the presence of prostate problems increases the risk.
Diseases such as depression, heart disease, arthritis, hypertension, benign prostatic hyperplasia, neurological disorders, prostatitis, mobility limitations, and recurrent urinary tract infections (UTIs) are predictors of overactive bladder in men. In women, depression, irritable bowel syndrome, neurological disorders, arthritis, sleep apnea, and recurrent urinary tract infections all have a greater possibility of being associated with an overactive bladder.
Additionally, behavioral and lifestyle factors also play a role in the development of an overactive bladder.
Key points to remember
- The publisher estimates that in 2019 there were 545.0 million prevalent cases of overactive bladder worldwide in adults aged 20 and over, and projects that number will rise to 607.6 million prevalent cases of overactive bladder. 2028.
- Drugs approved in the overactive bladder space target the calcium channel, the muscarinic acetylcholine receptor, SNARE proteins, and the beta-3 adrenergic receptor. The majority of these drugs are administered orally, with the rest available in intramuscular, intravesical, intradermal, intraarticular, topical, and transdermal formulations.
- The largest proportion of industry-sponsored drugs in active clinical development for overactive bladder are in Phase II, with no drugs in Phase III.
- Therapies being developed for overactive bladder focus on a wide variety of targets. The largest proportion of drugs in the pipeline are administered orally or intravesically, while a product is also tested in an intramuscular formulation.
- Upcoming high-impact events for drugs in the overactive bladder space include key Phase III trial results for Gemtesa and an estimated PDUFA date for Myrbetriq.
- The overall probability of approval of a Phase I urology-other asset is 9.3%, and the average probability of a drug progressing from Phase III is 75%. Drugs take an average of 10.0 years from Phase I to approval, compared to 9.0 years across the urology space as a whole.
- The distribution of clinical trials across phases I-IV indicates that just over half of overactive bladder trials were in the early and middle phases of development, with 54% of trials in phase I-II and 46 % in phase III-IV.
- The United States has a substantial lead in the number of overactive bladder clinical trials in the world. Germany dominates the main European markets, while Japan in first place in Asia.
- Clinical trial activity in the overactive bladder space is dominated by completed trials. Astellas has the most completed clinical trials for overactive bladder, with 176 trials. Astellas also leads the industry sponsors with the largest overall number of overactive bladder clinical trials, followed by Pfizer.
Main topics covered:
PREVIEW
KEY POINTS TO REMEMBER
DISEASE CONTEXT
PROCESSING
- Lifestyle modifications and control techniques
- Medical and surgical treatment
- Products and devices
EPIDEMIOLOGY
MARKETED MEDICINES
CURRENT MEDICATIONS
RECENT EVENTS AND ANALYST VIEWS
- BotuGel for Overactive Bladder (August 27, 2020)
MAIN UPCOMING EVENTS
KEY REGULATORY EVENTS
- Pediatric approval for Myrbetriq
- Vibegron approval to watch in Q4
LIKELIHOOD OF SUCCESS
LICENSING AND ASSET ACQUISITION GRANTS
- Eisai to sell Kyorin’s OAB agent in four Asian countries
- Urovant partners with Sunovion to commercialize Vigebron
INCOME OPPORTUNITY
CLINICAL TRIALS LANDSCAPE
- Sponsors by status
- Sponsors per phase
- Recent Events
BIBLIOGRAPHY
APPENDIX
For more information on this report visit https://www.researchandmarkets.com/r/a15jj4
Media Contact:
Research and Markets
Laura Woodsenior
[email protected]
For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900
US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716
SOURCE Research and Markets
